-
Machine Learning in Diagnosis and Prognosis of Lung Cancer by PET-CT
24 Apr 2024 03:06 GMT
… be used for lung tumor recognition, tumor … lung tumors, especially lung cancer lesions, due to the influence of respiratory movement, the lung tumors … intent chemoradiation in non-small cell lung cancer (NSCLC … drivers in lung cancers to select targeted …
-
Tislelizumab Earns European Approval in Non–Small Cell Lung Cancer
23 Apr 2024 17:43 GMT
… surgery and platinum-containing chemoradiation or those who have … treatment for non-small cell lung cancer. News release. BeiGene, … squamous non–small-cell lung cancer: a phase 3 randomized … treatment for non-small cell lung cancer. News release. BeiGene, Ltd …
-
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
23 Apr 2024 10:17 GMT
… for non-small cell lung cancer (NSCLC) across three indications … surgical resection or platinum-based chemoradiation, or metastatic NSCLC.
… .
“Non-small cell lung cancer remains one of the … lung cancers.2 In 2020, the number of new cases of lung cancer …
-
EU OK sets up first ex-China launches for BeiGene's Tevimbra
24 Apr 2024 09:45 GMT
… tislelizumab in non-small cell lung cancer (NSCLC), opening the door to … surgical resection or platinum-based chemoradiation or metastatic NSCLC.
The drug … surgical resection or platinum-based chemoradiation or metastatic NSCLC.
Finally, Tevimbra …
-
AstraZeneca’s Imfinzi tackles another type of lung cancer with latest trial win
05 Apr 2024 18:07 GMT
… small cell lung cancer and extensive-stage small cell lung cancer.
The … limited-stage small cell lung cancer (LS-SCLC). Compared … extensive-stage small cell lung cancer and demonstrate the … EGFR-mutated NSCLC following chemoradiation. And AZ expects results …
-
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
05 Apr 2024 11:50 GMT
… .
Notes
Small cell lung cancer
Lung cancer is the leading cause … IMFINZI in liver and lung cancers, the combination of … caregivers/lung-cancer-101/types-of-lung-cancer. Accessed … chemoradiation for patients with limited stage small cell lung cancer. …
-
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
05 Apr 2024 11:27 GMT
… .
Notes
Small cell lung cancer
Lung cancer is the leading cause … IMFINZI in liver and lung cancers, the combination of … caregivers/lung-cancer-101/types-of-lung-cancer. Accessed … chemoradiation for patients with limited stage small cell lung cancer. …
-
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
04 Apr 2024 11:01 GMT
… non-small cell lung cancers (adenocarcinoma). Despite … been challenging.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … resection or definitive chemoradiation either:
in …
-
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
28 Mar 2024 11:00 GMT
… patients with metastatic lung cancer, lung cancer continues to be … cycles.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … resection or definitive chemoradiation either:
in …
-
EC approves BeiGene’s tislelizumab for three NSCLC indications
23 Apr 2024 18:44 GMT
… treatment for non-small cell lung cancer (NSCLC). Tislelizumab, which is greenlit … surgical resection or platinum-based chemoradiation, or adults with metastatic NSCLC …